查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2002976

开放性青光眼治疗市场：依药物类别、治疗方法、给药途径、通路及最终用户划分－2026-2032年全球市场预测

Open-Angle Glaucoma Therapeutics Market by Drug Class, Therapy Type, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年开放性青光眼治疗市场价值为 102 亿美元，预计到 2026 年将成长至 111.2 亿美元，复合年增长率为 9.06%，到 ​​2032 年将达到 187.3 亿美元。

主要市场统计数据
基准年 2025 102亿美元
预计年份：2026年 111.2亿美元
预测年份 2032 187.3亿美元
复合年增长率 (%) 9.06%

对不断发展的开放性青光眼。

开放性青光眼仍然是全球范围内导致不可逆性视力丧失的主要原因之一，治疗方法也在不断发展，以满足未被满足的需求并适应技术进步。近年来，该领域的治疗方法已从单纯以眼压为中心的策略转向多方面综合策略，包括神经保护、患者用药依从性和联合治疗。这拓宽了临床医生和保险公司在实务中评估新药和给药方法时所依据的证据基础。

机制创新、先进的管理技术以及支付方期望的变化，正在从根本上重塑开放性青光眼。

开放性青光眼的治疗格局正经历着一场变革，这场变革是由科学、临床和商业性因素共同推动的。作用机制的创新，特别是Rho激酶抑制剂和其他标靶小梁网房水流出路径药物的出现，正在挑战传统药物长期以来的主导地位，并促使人们进行直接的疗效比较评估。同时，製剂和给药方法的改进，例如缓释植入植入和不含防腐剂的眼药水，正在重塑患者的用药依从性和临床实践。

2025 年关税对供应链变化带来的实际影响，以及为维持治疗的可及性、连续性和商业性势头而采取的策略应对措施。

2025年即将实施的新关税将进一步增加治疗药物和医疗设备的商业复杂性，这些药物和医疗器材依赖来自世界各地的零件和活性成分。进口关税的增加推高了原材料和成品的采购成本，促使采购团队重新评估其供应商组合，并考虑双重采购和地域多元化策略，以维持盈利能力和供应的连续性。为此，一些製造商正在加速推动近岸外包和契约製造伙伴关係，以降低关税波动带来的风险。

细分市场证据优先事项和商业化槓桿源自于药物类别、治疗方法类型和给药途径，这些因素决定了治疗药物的差异化。

精准理解药物细分对于合理定位资产、优先考虑跨药物类别、治疗方法类型和给药途径的临床和商业投资至关重要。在各类药物中，应考虑许多研究领域，包括α受体阻断剂、 β阻断剂、碳酸酐酶抑制剂、固定剂量组合药物、前列腺素类似物和Rho激酶抑制剂。 ββ阻断剂类别再细分为倍他洛尔、美替洛尔和噻吗洛尔，而前列腺素类似物则包括Bimatoprost、拉坦前列素、他氟前列素和曲伏前列素。这些区分至关重要，因为机制特异性的安全性和耐受性特征以及潜在的差异化优势会影响关于临床定位和处方集的讨论。

美洲、欧洲、中东和非洲以及亚太地区在监管、支付方框架和供应链趋势方面的细微差异，如何影响差异化的市场进入和成长策略？

区域趋势对监管路径、报销方式和商业性实施有显着影响，因此美洲、欧洲、中东、非洲和亚太地区需要製定量身定制的策略。在美洲，价格谈判、支付方协议和病患支援体係是影响药物可及性和推广的关键因素，而临床实务模式和眼科转诊网络则决定了新型作用机制和缓释製剂的采纳曲线。

一种竞争定位和伙伴关係模式，能够使青光眼治疗领域的相关人员（製药公司、生物技术公司和医疗设备製造商）实现可持续的差异化。

开放性青光眼治疗市场的竞争格局由大型製药企业、专业生物技术公司和医疗设备製造商组成，它们各自寻求在临床和商业上脱颖而出的途径。成熟的大型公司通常利用其广泛的分销网络、临床试验经验和与支付方的良好关係来支援渐进式创新和生命週期管理。相较之下，规模较小的生物技术公司则专注于具有单一作用机制的突破性成果、灵活的研发进度以及策略伙伴关係，以降低规模化生产和市场准入方面的风险。

针对研发、商业规划和供应链韧性等方面的优先考虑，提出了极具影响力和可操作性的建议，以加快招聘速度并确保就业机会。

产业领导企业应采取协作策略，将科学差异化、商业性执行和供应链韧性结合在一起。优先开发那些与现有标准疗法相比具有明显耐受性和依从性优势的药物，并设计临床试验以获得对临床医生、支付方和患者都有意义的终点指标。这包括将生活品质 (QOL) 和依从性指标纳入主要试验，并规划从早期阶段就收集真实世界数据 (REW)。

一种透明且可重复的调查方法，将与专家的直接访谈与全面的二手证据相结合，以支持策略决策。

本报告整合了第一手和第二手研究方法，建构了一个稳健且多方验证的证据基础。第一手研究包括对临床医生、支付方、采购专业人员和行业高管进行结构化访谈，并辅以咨询委员会的意见和来自销售团队的实地洞察。第二手研究则利用了同行评审文献、监管指导文件、临床试验註册信息以及公开的企业资讯披露，以分析临床开发趋势和市场准入驱动因素。

这明确地整合了领导者必须解决的营运挑战，以将治疗方法创新、证据优先排序和进展转化为可持续的临床和商业性成功。

总而言之，开放性青光眼治疗市场正进入一个机会与挑战并存的阶段，其驱动因素包括作用机制的创新、给药方式的进步以及支付方期望的转变。能够整合差异化临床价值、永续给药方案和可靠的真实世界证据的公司，将更有利于影响临床实践并确保获得报销。同时，贸易趋势和区域差异也要求企业制定积极主动的供应链规划和区域性市场策略。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：开放性青光眼治疗市场：依药物类别划分

  • α-激动剂
  • β阻断剂
    • 倍他索
    • 甲羟戊酸
    • 蒂莫罗尔
  • 碳酸酐酶抑制剂
  • 固定剂量组合药物
  • 前列腺素类似物
    • Bimatoprost
    • 拉坦前列素
    • 塔福普罗斯特
    • 曲前列素
  • Rho激酶抑制剂

第九章：依治疗方法开放性青光眼治疗市场

  • 联合治疗
    • β阻断剂与摄护腺素
    • 碳酸酐酶抑制剂和β阻断剂
  • 单药治疗

第十章：开放性青光眼治疗市场：依给药途径划分

  • 静脉
  • 口服
  • 局部的

第十一章：开放性青光眼治疗市场：依分销管道划分

  • 医院药房
  • 零售药房
  • 网路药房
  • 专科药房
  • 邮购药房

第十二章：开放性青光眼治疗市场：依最终用户划分

  • 医院
    • 三级医疗机构
    • 当地医院
  • 门诊手术中心
  • 眼科诊所
  • 验光诊所
  • 学术和研究机构

第十三章：开放性青光眼治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章开放性青光眼治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：开放性青光眼治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国开放性青光眼治疗市场

第十七章：中国开放性青光眼治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Aerie Pharmaceuticals, Inc.
  • Alcon Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-957C47F9384B

The Open-Angle Glaucoma Therapeutics Market was valued at USD 10.20 billion in 2025 and is projected to grow to USD 11.12 billion in 2026, with a CAGR of 9.06%, reaching USD 18.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.20 billion
Estimated Year [2026] USD 11.12 billion
Forecast Year [2032] USD 18.73 billion
CAGR (%) 9.06%

A concise and authoritative orientation to the evolving therapeutic landscape, unmet needs, and strategic imperatives shaping open-angle glaucoma care

Open-angle glaucoma remains a leading cause of irreversible vision loss worldwide, and therapeutics development continues to evolve in response to unmet clinical needs and technological progress. In recent years, the field has witnessed a shift from solely intraocular pressure-centric approaches to multidimensional strategies that consider neuroprotection, patient adherence, and combination regimens. This has broadened the evidence base that clinicians and payers evaluate when integrating new agents and delivery modalities into practice.

The introduction of novel mechanisms of action, advances in sustained-delivery systems, and an expanding emphasis on real-world outcomes have collectively reshaped clinical expectations and commercial models. Consequently, stakeholders across pharmaceutical, biotechnology, and medical device sectors are re-evaluating go-to-market plans, evidence-generation strategies, and partnerships. This introduction sets the stage for a focused exploration of the transformative shifts, regulatory and trade dynamics, segmentation nuances, regional considerations, and strategic actions that will define the therapeutic landscape in the near term.

How mechanistic innovation, advanced delivery technologies, and evolving payer expectations are fundamentally reshaping open-angle glaucoma therapeutic strategy and adoption

The therapeutic landscape for open-angle glaucoma is undergoing transformative shifts driven by converging scientific, clinical, and commercial forces. Mechanistic innovation, particularly the emergence of Rho kinase inhibitors and other agents targeting trabecular outflow, challenges the long-standing dominance of traditional classes and invites head-to-head comparative effectiveness assessments. At the same time, improvements in drug formulation and delivery - including sustained-release implants and preservative-free topical options - are reshaping adherence patterns and clinical practice.

Concurrently, payer expectations and regulatory pathways are evolving, incentivizing robust real-world evidence and health-economic evaluations. Innovations in diagnostics, such as enhanced imaging and home-monitoring technologies, are enabling earlier detection and more individualized treatment adjustments. These combined trends are prompting a strategic realignment across life sciences companies and clinics: research and development pipelines are being prioritized for agents with demonstrable durability and tolerability advantages, commercial models are emphasizing patient support and adherence solutions, and partnerships between pharmaceutical and device manufacturers are becoming more common to deliver integrated care solutions.

Practical implications of tariff-driven supply chain shifts in 2025 and strategic responses that preserve access, continuity, and commercial momentum for therapeutics

The imposition of new tariffs in 2025 has introduced an additional layer of commercial complexity for therapeutics and devices that rely on globally sourced components and active pharmaceutical ingredients. Increased duties on imports can elevate the landed cost of raw materials and finished products, prompting procurement teams to reassess supplier portfolios and consider dual sourcing or regionalization strategies to preserve margin and supply continuity. In response, some manufacturers are accelerating nearshoring and contract manufacturing partnerships to mitigate exposure to tariff volatility.

Beyond direct cost impacts, tariffs influence strategic timelines and product launch sequencing. Companies may adjust supply chain footprints to prioritize markets with lower trade friction or to insulate critical production lines from tariff-related disruptions. This environment also amplifies the importance of contractual protections, such as long-term supply agreements and price adjustment clauses. From a clinical perspective, tariffs can indirectly affect access by increasing list prices or constraining the availability of certain imported formulations, thereby necessitating expanded patient assistance programs and adaptive reimbursement negotiations. Overall, the tariff landscape underscores the need for dynamic commercial strategies that integrate trade risk assessment, supply chain resilience, and proactive stakeholder engagement.

Segment-specific evidence priorities and commercialization levers drawn from drug classes, therapy types, and administration routes that shape therapeutic differentiation

A nuanced understanding of segmentation is essential to position assets and prioritize clinical and commercial investments across drug classes, therapy types, and routes of administration. Based on drug class, study considerations span Alpha Agonists, Beta Blockers, Carbonic Anhydrase Inhibitors, Fixed Dose Combinations, Prostaglandin Analogues, and Rho Kinase Inhibitors, with the Beta Blockers category further disaggregated into Betaxolol, Metipranolol, and Timolol, and Prostaglandin Analogues examined across Bimatoprost, Latanoprost, Tafluprost, and Travoprost. These distinctions matter because mechanism-specific safety and tolerability profiles, as well as differentiation potential, influence clinical positioning and formulary discussions.

Based on therapy type, the market perspective encompasses Combination Therapy and Monotherapy, where Combination Therapy merits closer scrutiny for regimens such as Beta Blocker And Prostaglandin and Carbonic Anhydrase Inhibitor And Beta Blocker. Combination strategies often seek to improve intraocular pressure control while simplifying regimens to enhance adherence, which can materially affect real-world effectiveness. Based on route of administration, the clinical and commercial dialogue must address Intravenous, Oral, and Topical approaches, each of which carries unique considerations for delivery technology, patient acceptance, safety monitoring, and distribution logistics. Taken together, segmentation insights should drive targeted evidence generation and commercial differentiation for any candidate therapy.

How regional regulatory nuances, payer frameworks, and supply chain dynamics across the Americas, EMEA, and Asia-Pacific inform differentiated market entry and growth strategies

Regional dynamics materially influence regulatory pathways, reimbursement approaches, and commercial execution, requiring tailored strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, pricing negotiations, payer contracting, and patient support infrastructure are critical determinants of access and uptake, while clinical practice patterns and ophthalmology referral networks shape the adoption curve for new mechanisms and sustained-delivery systems.

In Europe, Middle East & Africa, diverse regulatory regimes and reimbursement criteria necessitate robust health-economic dossiers and region-specific real-world evidence. Market entry strategies must account for heterogeneous procurement processes and variable hospital purchasing practices across countries. In the Asia-Pacific region, regulatory modernization, growing biotech investment, and a rising focus on locally manufactured products create opportunities for collaboration and regional manufacturing. Across all geographies, supply chain resilience, local clinical data generation, and culturally attuned patient support programs are core enablers of sustained adoption and commercial success.

Competitive positioning and partnership models that enable durable differentiation across pharmaceutical, biotech, and device stakeholders in glaucoma therapeutics

Competitive dynamics in the open-angle glaucoma therapeutics space are shaped by a mix of large pharmaceutical companies, specialty biotechs, and device-focused manufacturers, each pursuing distinct routes to clinical and commercial differentiation. Established players typically leverage broad distribution networks, clinical trial experience, and payer relationships to support incremental innovations and lifecycle management. In contrast, smaller biotechs emphasize single-mechanism breakthroughs, nimble development timelines, and strategic partnerships to de-risk scale-up and access pathways.

Collaboration models are increasingly prevalent: co-development and licensing agreements bring together formulation expertise, delivery platforms, and commercialization capabilities. Meanwhile, device manufacturers that deliver sustained-release implants or novel administration systems are collaborating with drug developers to offer integrated solutions that address adherence and durability. Successful companies are those that align clinical development with pragmatic evidence generation, engage early with payers and key opinion leaders, and invest in patient-centric support services that reinforce real-world outcomes and reduce treatment discontinuation.

High-impact, actionable recommendations for R&D prioritization, commercial planning, and supply chain resilience to accelerate adoption and protect access

Industry leaders should pursue a coordinated strategy that aligns scientific differentiation with commercial execution and supply chain resilience. Prioritize development programs that address clear tolerability or adherence advantages over existing standards of care and design clinical trials to capture endpoints meaningful to clinicians, payers, and patients. This includes integrating quality-of-life measures and adherence metrics into pivotal studies and planning for real-world evidence generation from the outset.

From a commercial perspective, invest in patient support systems, clinician education, and value demonstration to build compelling reimbursement narratives. Strengthen supplier relationships and diversify manufacturing footprints to mitigate tariff and trade risks, and evaluate regional manufacturing or contract development and manufacturing organization partnerships where appropriate. Pursue strategic collaborations that combine delivery technology with pharmacologic innovation, and engage payers early to align on evidence requirements and pricing strategies. Finally, maintain adaptive launch sequencing and portfolio prioritization that reflects regional regulatory timelines, procurement environments, and local clinical practice patterns.

Transparent and reproducible research methods combining expert primary interviews and comprehensive secondary evidence to inform strategic decision-making

The report synthesizes primary and secondary research methods to create a robust, triangulated evidence base. Primary research included structured interviews with clinicians, payers, procurement specialists, and industry executives, complemented by advisory-board consultations and field-level insights from commercial teams. Secondary research drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, and publicly available company disclosures to contextualize clinical development trends and market-access drivers.

Data from these sources were triangulated to reconcile differing perspectives and validate strategic conclusions. Quality-control measures included cross-validation of interview findings, reproducibility checks for analytical models, and a governance process for expert review. Where gaps existed, targeted follow-up interviews were conducted to ensure the analysis reflected current practice and regulatory dynamics. The methodology emphasizes transparency and reproducibility while prioritizing practical insights that inform clinical development, commercialization, and policy strategy.

A conclusive synthesis of therapeutic innovation, evidence priorities, and operational imperatives that leaders must address to translate advances into sustained clinical and commercial success

In summary, the open-angle glaucoma therapeutics landscape is entering a phase where mechanistic innovation, delivery advances, and evolving payer expectations converge to create both opportunity and complexity. Companies that integrate differentiated clinical value with durable delivery solutions and robust real-world evidence will be best positioned to influence clinical practice and secure reimbursement. Simultaneously, trade dynamics and regional heterogeneity require proactive supply chain planning and localized market strategies.

Achieving sustained impact will depend on aligning R&D priorities with pragmatic evidence generation, engaging stakeholders across the care pathway early, and deploying patient-centric commercial programs that support adherence and long-term outcomes. Decision-makers who adopt an integrated approach-combining scientific differentiation, commercial rigor, and operational resilience-will be able to translate therapeutic innovation into improved patient care and durable business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Open-Angle Glaucoma Therapeutics Market, by Drug Class

  • 8.1. Alpha Agonists
  • 8.2. Beta Blockers
    • 8.2.1. Betaxolol
    • 8.2.2. Metipranolol
    • 8.2.3. Timolol
  • 8.3. Carbonic Anhydrase Inhibitors
  • 8.4. Fixed Dose Combinations
  • 8.5. Prostaglandin Analogues
    • 8.5.1. Bimatoprost
    • 8.5.2. Latanoprost
    • 8.5.3. Tafluprost
    • 8.5.4. Travoprost
  • 8.6. Rho Kinase Inhibitors

9. Open-Angle Glaucoma Therapeutics Market, by Therapy Type

  • 9.1. Combination Therapy
    • 9.1.1. Beta Blocker And Prostaglandin
    • 9.1.2. Carbonic Anhydrase Inhibitor And Beta Blocker
  • 9.2. Monotherapy

10. Open-Angle Glaucoma Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Topical

11. Open-Angle Glaucoma Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Online Pharmacies
  • 11.4. Specialty Pharmacies
  • 11.5. Mail-Order Pharmacies

12. Open-Angle Glaucoma Therapeutics Market, by End User

  • 12.1. Hospitals
    • 12.1.1. Tertiary Care Hospitals
    • 12.1.2. Community Hospitals
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Ophthalmology Specialty Clinics
  • 12.4. Optometry Practices
  • 12.5. Academic And Research Centers

13. Open-Angle Glaucoma Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Open-Angle Glaucoma Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Open-Angle Glaucoma Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Open-Angle Glaucoma Therapeutics Market

17. China Open-Angle Glaucoma Therapeutics Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Aerie Pharmaceuticals, Inc.
  • 18.7. Alcon Inc.
  • 18.8. Merck & Co., Inc.
  • 18.9. Novartis AG
  • 18.10. Pfizer Inc.
  • 18.11. Santen Pharmaceutical Co., Ltd.
  • 18.12. Sun Pharmaceutical Industries Ltd.
  • 18.13. Teva Pharmaceutical Industries Ltd.
  • 18.14. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ALPHA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETAXOLOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY METIPRANOLOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TIMOLOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY FIXED DOSE COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BIMATOPROST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY LATANOPROST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TAFLUPROST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TRAVOPROST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RHO KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKER AND PROSTAGLANDIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MAIL-ORDER PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MAIL-ORDER PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY MAIL-ORDER PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY TERTIARY CARE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPTOMETRY PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPTOMETRY PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY OPTOMETRY PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ACADEMIC AND RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ACADEMIC AND RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ACADEMIC AND RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 199. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 201. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 203. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 232. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 233. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. G7 OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 239. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 242. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 243. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY BETA BLOCKERS, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY PROSTAGLANDIN ANALOGUES, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA OPEN-ANGLE GLAUCOMA THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)